The introduction of the FOLFIRINOX regimen within the last decade marked the first
progress in the clinical field of metastatic pancreatic cancer which had not seen any …

Background and aims Sarcopenia is an important prognostic factor for cancer patients. Here,
we assessed the effects of sarcopenia on progression-free survival (PFS) and overall …

Background/Aim: The acidic tumor microenvironment is associated both with the
progression and drug resistance of cancer. We aimed to investigate the effects of …

Pancreatic cancer (PC) incidence rates are rapidly increasing in developed countries, with
half the patients being metastatic at diagnosis. For decades, fluorouracil, then gemcitabine …

Background The efficacy of modified FOLFIRINOX (mFOLFIRINOX) as a second-line
chemotherapy treatment for metastatic pancreatic adenocarcinoma (mPAC), remains …

Background/Aim: The aim of this study was to investigate the safety and feasibility of
neoadjuvant nab-paclitaxel plus gemcitabine therapy for patients with borderline resectable …

The hepatotoxicity of irinotecan is drawing wide concern nowadays due to the widespread
use of this chemotherapeutic against various solid tumors, particularly metastatic colorectal …

Background FOLFIRINOX (FX) has been reported as an effective treatment for unresectable
advanced pancreatic cancer. However, FX is associated with a high incidence of adverse …

Purpose New chemotherapies have become available for the treatment of advanced
pancreatic cancer and have led to changes in its standard treatments. Since pancreatic …

Objectives The aim of this study was to compare the efficacy and safety of FOLFIRINOX (5-
FU/leucovorin, irinotecan, and oxaliplatin) and gemcitabine/nab-paclitaxel (GnP) in patients …